Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
US7329673B2 · kind B2 · utility
1Cited by
3References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2004 |
| Grant date | Feb 12, 2008 |
| Priority date | — |
| Expiry date | Aug 20, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Certain novel N-acylated spiropiperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.